Top advances of the year: Breast cancer.

Although breast cancer has led the way toward precision medicine, more research is still needed to increase curation rates in patients with early disease and to prolong survival with an optimal quality of life in the metastatic setting. Last year, big advances were achieved toward these goals thanks to the significant impact of immunotherapy on survival in triple‐negative breast cancer and the exciting results of antibody‐drug conjugates. Plain Language Summary: The development of new drugs and biomarkers to select those patients who will benefit of them are crucial in improving survival in breast cancer.Last year, the emergence of antibody‐drug conjugates and the reaffirmation of the potential of immunotherapy in breast cancer were the most important findings. The definitive establishment of immunotherapy in triple‐negative breast cancer and the amazing results of the new antibody‐drug conjugates are the main landmarks in 2021 and 2022, and constitute the beginning of a new era in the treatment of breast cancer. [ABSTRACT FROM AUTHOR]